Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.

Author(s): Rog DJ, Nurmikko TJ, Young CA

Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom. [email protected]

Subject: Multiple Sclerosis View the study


Central neuropathic pain (CNP), pain initiated or caused by a primary lesion or dysfunction of the central nervous system, occurs in ~28% of patients with multiple sclerosis (MS). Delta(9)-Tetrahydrocannabinol/cannabidiol (THC/CBD), an endocannabinoid system modulator, has demonstrated efficacy for up to 4 weeks in randomized controlled trials in the treatment of CNP in patients with MS.

Source: Clinical Therapeutics (Price: $36)
Share Tweet

More medical studies related to Multiple Sclerosis:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.